OncoSec Medical Incorporated · OTC:ONCSQ

OncoSec Medical — Investor Presentation (March 2021)

34 slides from OncoSec Medical's investor presentation, March 2021

  1. Slide 1: Powerful, Tumor-agnostic Immunotherapy Treatment

    Powerful, Tumor-agnostic Immunotherapy Treatment ONCOSEC’S PLATFORM TO ATTACK VISCERAL, CUTANEOUS AND SUBCUTANEOUS TUMORS NASDAQ: ONCS MARCH 2021

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS To the extent statements contained in the following retain key scientific or management personnel; (viii) presentations are not descriptions of historical facts the anticipated timing of clinical data availability; (ix) regarding OncoSec Medical Incorporated, they should t

  3. Slide 3: Investment Highlights

    Ticker: NASDAQ: ONCS Investment Highlights Market Cap (as of 3/22/21): ~$211M Stock Price (as of 3/22/21): $5.69 Shares Outstanding (as of 3/22/21): ~37M • Biotechnology company focused on intratumoral (IT) delivery of DNA-based immunotherapies as monotherapy and in combination regimes • Developing

  4. Slide 4: The Promise of Immunotherapy Has Yet to Be Fully Realized

    How Checkpoint Inhibitors Work The Promise of Molecular switches known as Immunotherapy Has Yet 1 checkpoints normally prevent T- cells from attacking healthy tissue to Be Fully Realized When these checkpoints, such as 2 PD-1 and PD-L1, are hijacked by cancer cells, the immune system’s T-cell respon

  5. Slide 5: Checkpoint Non-response in 60-90% of Cases

    Checkpoint Powerful drugs (like KEYTRUDA®) have been highly Non-response successful for some patients, but not the majority in 60-90% 90% of cancers are solid tumors. Of these: of Cases % OF CHECKPOINT TUMOR TYPE NON-RESPONDERS MELANOMA ˜60-80% ~30% ~70% Hot Tumors Cold Tumors TRIPLE NEGATIVE BREAST

  6. Slide 6: TAVO is Capable of Reversing Resistance to Checkpoint Therapies

    TAVO (plasmid-based interleukin-12) is administered locally at the tumor site using OncoSec’s gene TAVO™ is Capable of electro therapy (GET) delivery system. TAVO is designed to induce local expression of IL-12, turning Reversing Resistance “cold” tumors “hot” and enabling checkpoint to Checkpoint t

  7. Slide 7: IL-12 Is a Key Mediator of Communication Between Innate and Adaptive Cells

    IL-12 IS A KEY MEDIATOR OF COMMUNICATION BETWEEN DC/MACROPHAGES (INNATE) & EFFECTOR T CELLS AND NK CELLS (ADAPTIVE) Lasek W, et al, Cancer Immunol Immunother 2014

  8. Slide 8: Benefits of Gene Electro Transfer (GET) System

    Benefits of Gene Electro Transfer (GET) System A non-invasive, Rapid Transfection Versatile non-chemical, More rapid than Wide array of molecules can traditional chemical or be transfected, and can be non-toxic method biologic cell transfection applied to a broad selection techniques of cell types t

  9. Slide 9: Seamless Delivery Of Plasmid IL-12

    Generator Seamless • Fixed electrical field intensity Delivery Of • Momentary electrical pulses (100 µsec duration and 300 millisecond interval) Plasmid IL-12 • Pulses activated by foot switch • 16 lbs. 12.5” w x 5.5” h x 13” d + Energy Step 3: Electroporation Electrical pulses, activated by a foot

  10. Slide 10: Gene Electro Transfer of Immunotherapy: An Intratumoral IL-12 Factory

    Gene Electro Transfer of Immunotherapy: An Intratumoral IL-12 Factory The IL-12 Factory DNA plasmid IL-12 is injected into the IL-12/IFN𝛾𝛾 Feed Forward Loop tumor, followed by Tumors express IL-12 a 3 sec. pulse of stimulating NK and T energy cells to make IFN-𝛾𝛾, which then feeds Tumor cells…

  11. Slide 11: TAVO: A Tumor Agnostic Platform with Single Agent Activity

    5 TAVO: A Tumor Agnostic CLINICAL/ IMMUNOLOGICAL SIGNAL IN FIVE TUMOR TYPES Platform with Single Agent Activity TAVO + PEMBRO COMBINATION TAVO SINGLE AGENT SPONSORED TRIALS INVESTIGATOR-SPONSORED TRIALS Metastatic Melanoma Metastatic TNBC U.S. Orphan Accelerated Approval Metastatic Metastatic Fast T

  12. Slide 12: Clinical Pipeline is Well Diversified with Multiple Growth Opportunities

    Clinical Pipeline is Well Diversified with Multiple Growth Opportunities REGIMEN TRIAL INDICATION N PARTNER PHASE 1 PHASE 2 PIVOTAL TAVO + Checkpoint Resistant KEYNOTE-695 ~100 pembrolizumab Metastatic Melanoma TAVO + Triple Negative Breast KEYNOTE-890 ~65 pembrolizumab Cancer (TNBC) TAVO + TAVO™ CO

  13. Slide 13: FDA Fast Track KEYNOTE-695

    FDA Fast Track KEYNOTE-695 Ongoing pivotal trial in PD-1 checkpoint resistant metastatic melanoma provides a pathway towards accelerated approval GRANTED FAST TRACK AND ORPHAN DRUG DESIGNATIONS Fast-track makes Program for Must meet RECIST TAVO™ eligible patients with no (tumor shrinkage) for accele

  14. Slide 14: KEYNOTE-695 Trial Design and Eligibility

    Up To Number Of 30 Sites PATIENTS TO BE TREATED 100 Canada Italy United States Australia DEFINITIVE CLINICAL PROGRESSION ON FULL COURSE ANTI-PD-1 Stage 3/4 Received at Progressive Documented No intervening Eligible Melanoma therapies permitted patient/definitive least 12 weeks + disease + disease +

  15. Slide 15: Patient Demographics and Disease Characteristics

    Patient Demographics and Disease Characteristics ‡Based on maximum value prior to dosing; #2 patients with ≥ 2X ULN Fernandez-Peñas, P. et al., SITC Annual Meeting 2020, data as of September, 2020 15

  16. Slide 16: 5 of 54 Evaluable Patients had 100% Tumor Reduction

    Investigator-Assessed Response per Recist v1.1 – Preliminary Data 5 of 54 Evaluable Patients had 100% Tumor Reduction Fernandez-Peñas, P. et al., SITC Annual Meeting 2020 data as of September, 2020 16

  17. Slide 17: Treatment-Related Adverse Events (TRAE) in ≥ 5% of Patients

    Treatment–Related Adverse Events (TRAE) in ≥ 5% of Patients All Grades n(%) (N=56) Grade 1/2 Grade 3 Grade 4 Grade 5 Patients with at least one TEAE 43 (76.8%) 40 (71.4%) 3 (5.4%) - - Fatigue 15 (26.8%) 15 (26.8%) - - - Procedural pain 13 (23.2%) 13 (23.2%) - - - Diarrhea 11 (19.6%) 11 (19.6%) - - -

  18. Slide 18: Treated and Untreated Lesions from Responding Patients

    Treated and Untreated Lesions from 16 Responding Patients Fernandez-Peñas, P. et al., SITC Annual Meeting 2020, data as of September, 2020 18

  19. Slide 19: Actively Progressing Patients & Short Interval Between Last Anti-PD-1 Dose and Study Treatment

    Actively Progressing Patients & Short Interval Between the Last Dose of Anti-PD-1 and Study Treatment Fernandez-Peñas, P. et al., SITC Annual Meeting 2020,19 Data as of September, 2020

  20. Slide 20: Actively Growing Lesions Significantly Reduced in Size after pIL-12 + Pembrolizumab

    Actively Growing Lesions Significantly Reduced in Size after pIL-12 + Pembrolizumab Treatment Fernandez-Peñas, P. et al., SITC Annual Meeting 2020, data as of September, 2020 20

  21. Slide 21: Pseudo Progression in Target Lesion followed by Tumor Response

    Pseudo Progression in Target Lesion followed by tumor Response [Stage IVB; PR (-93%)] Fernandez-Peñas, P. et al., SITC Annual Meeting 2020, data as of September, 2020 21

  22. Slide 22: Progression on Ipi/Nivo Followed by Tumor Response

    Progression on Ipi/Nivo Followed by Tumor Response[Stage IVC; PR (-53%)] Fernandez-Peñas, P. et al., SITC Annual Meeting 2020, data as of September, 2020 22

  23. Slide 23: US Market Opportunity: Focusing First on Metastatic Melanoma

    US Market Focusing First on Metastatic Melanoma Opportunity in the United States 91,000 diagnosis 9,000 deaths each year each year 90% of all cancer cases are solid tumors Incidence of melanoma US melanoma market on the projected to almost 1.6M new cases of solid tumors in the US rise (1.4% yearly f

  24. Slide 24: Commercialization by 2022 Targeted

    Commercialization by 2022 Targeted 2021 2022 Pre-BLA Meeting Projected FDA Accelerated with FDA Approval of TAVO for Metastatic Melanoma Potential US TAVO is US Orphan Designated 2021/22 and Keynote-695 is fast Regulatory Planned submission of tracked. OncoSec will seek Timeline BLA for Accelerated

  25. Slide 25: Expanding KEYNOTE-890 into First-Line mTNBC

    Expanding KEYNOTE-890 into First-Line mTNBC Primary Endpoint: ORR by blinded independent central PHASE 2 COHORT 1 COHORT 2 review (BICR) based Multi-cohort, open-label study TAVO and KEYTRUDA on RECIST v1.1 TAVO and KEYTRUDA plus of TAVO in combination with in patients with heavily Chemotherapy in p

  26. Slide 26: Case #1: TNBC BOR: CR (-100.0%)

    CASE #1: TNBC BOR: CR (-100.0%) Total # Baseline Max tumor Age Sex Metastasis Prior Rx EOT of priors SLD (mm) reduction 35 F Liver, skin, LN 3 Paclitaxel; dox + cyclopho + goserelin; capecitabine 84.5 -100 Ongoing LDH at 1 non target skin nodule was treated with PD-L1 IL-12 EP. Three liver target le

  27. Slide 27: Case #2: TNBC BOR: PR (-67.0%)

    CASE #2: TNBC BOR: PR (-67.0%) Total # Baseline Max Tumor Age Sex Metastasis Prior Rx EOT of priors SLD (mm) reduction Breast, lung, lymph Paclitaxel: capecitabine: eribulin; 46 F 5 116 -67 Ongoing node cyclo + dox: carbo + gem LDH at PD-L1 Baseline Baseline C9D1 251 Negative Partial response 25 Com

  28. Slide 28: Recent Peer Reviewed Publications

    Recent Peer Reviewed Publications *Click thumbnails to access full articles TAVO + PEMBRO IN ANTICIPATED TAVO SINGLE AGENT ABSCOPAL EFFECT ANTI-PD-1 CHECKPOINT FAILURES 28

  29. Slide 29: VLA Highlights

    VLA Highlights 1 Rigid and catheter models: Used with bronchoscope, cystoscope, and trocar 2 Prototype successfully tested in large animal model: bone, pancreas, liver, lung, & bladder NEEDLE/ELECTRODES EXPANDED ENTERS THE ORGAN DRUG DELIVERY GENE ELECTROTRANSFER 1 2 3 29

  30. Slide 30: OncoSec Catheter VLA

    ONCOSEC CATHETER VLA VISCERAL LESION APPLICATOR A P P L I C A B L E I N D I C AT I O N S Lung Bladder GI Tract BRONCHOSCOPE CYSTOSCOPE ENDOSCOPE A P P L I C ATO R M E A S U R E M E N T S Electrode Width Electrode Length Injection Needle 4.5mm (+/- 0.5mm) 8mm (+/- 0.5mm) 4mm (+/- 1mm) May reduce leng

  31. Slide 31: OncoSec Rigid VLA

    ONCOSEC RIGID VLA A P P L I C A B L E I N D I C AT I O N S VISCERAL LESION APPLICATOR Liver Bone Pancreas A P P L I C ATO R M E A S U R E M E N T S Electrode Width Electrode Length Injection Needle 4.5mm (+/- 0.5mm) 8mm (+/- 0.5mm) 4mm (+/- 1mm) May reduce length depending on application 4.5mm LIVER

  32. Slide 32: Strong Financial Position to Achieve Near Term Milestones

    Strong Financial Position to Achieve Near Term Milestones ~$60M in Cash as of 1/31/21 No debt • Filing of new IND for second product candidate combining IL-12 with CXCL9 • FDA clearance GenPulse, the planned go-to-market generator • Commencing Phase 3 clinical trial of TAVO + pembro in metastatic me

  33. Slide 33: Established Biotech Leaders

    Established Biotech Leaders BOARD OF DIRECTORS WITH A TRACK RECORD OF SUCCESS Daniel J. O’Connor, JD Chief Executive Officer & Director MANAGEMENT Margaret R. Dalesandro, Ph.D. Chair Robert W. Kim Jaffe, Ph.D Herbert Kim Lyerly, M.D. Daniel J. O’Connor President/Director/CEO Ashworth, Ph.D Assistant

  34. Slide 34: Thank You

    Thank You Brian Leuthner CHIEF OPRERATING OFFICER 908.531.4566 [email protected] HEADQUARTERS LAB & RESEARCH 24 NORTH MAIN STREET 3565 GENERAL ATOMICS CT. PENNINGTON, NJ SAN DIEGO, CA

OncoSec Medical — Investor Presentation (March 2021) on 6ix